Abstract

 CADTH recommends that Intrarosa should be reimbursed by public drug plans for the treatment of postmenopausal vulvovaginal atrophy (VVA) if certain conditions are met.
 Intrarosa should only be covered for patients who are eligible for vaginal estrogen products that are currently reimbursed by public drug plans for the treatment of postmenopausal VVA.
 Intrarosa should only be reimbursed if treatment with Intrarosa does not cost more than treatment with the least costly vaginal estrogen product currently reimbursed for the treatment of postmenopausal VVA.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
